Tuberculosis Research and Treatment
Volume 2010 (2010), Article ID 284028, 5 pages
doi:10.1155/2010/284028
Research Article

Management of Latent Tuberculosis Infections in Australia and New Zealand: A Review of Current Practice

Justin T. Denholm1,2,3 and Emma S. McBryde1,2

1Victorian Infectious Diseases Service, Royal Melbourne Hospital, Grattan Street, Parkville, VIC, 3050, Australia
2Department of Medicine, University of Melbourne, Parkville, VIC, 3010, Australia
3Anton Breinl Centre, James Cook University, Townsville, QLd, 4810, Australia

Received 17 May 2010; Revised 11 October 2010; Accepted 14 December 2010

Academic Editor: Jeffrey R. Starke

Copyright © 2010 Justin T. Denholm and Emma S. McBryde. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Dye, S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione, “Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country,” Journal of the American Medical Association, vol. 282, no. 7, pp. 677–686, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Jasmer, P. Nahid, and P. C. Hopewell, “Latent tuberculosis infection,” New England Journal of Medicine, vol. 347, no. 23, pp. 1860–1866, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. “Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International union against tuberculosis committee on prophylaxis,” Bulletin of the World Health Organization, vol. 60, no. 4, pp. 555–564, 1982.
  4. K. E. Dooley and T. R. Sterling, “Treatment of latent tuberculosis infection: challenges and prospects,” Clinics in Chest Medicine, vol. 26, no. 2, pp. 313–326, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. Murray, J. Davis, V. Krause, et al., Diagnosis, Management and Prevention of Infections in Recently Arrived Refugees, Dreamweaver, Sydney, Australia, 2009.
  6. C. M. Nolan, S. V. Goldberg, and S. E. Buskin, “Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic,” Journal of the American Medical Association, vol. 281, no. 11, pp. 1014–1018, 1999. View at Publisher · View at Google Scholar
  7. F. F. Fountain, E. Tolley, C. R. Chrisman, and T. H. Self, “Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic,” Chest, vol. 128, no. 1, pp. 116–123, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. J. Saukkonen, D. L. Cohn, R. M. Jasmer et al., “An official ATS statement: hepatotoxicity of antituberculosis therapy,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 8, pp. 935–952, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. D. Pradeep, G. P. R. Clunie, K. Gaffney et al., “Screening for Mycobacterium tuberculosis prior to anti-TNF therapy—an audit of impact of the British Thoracic Society guidelines on rheumatology practice in an area of low Mycobacterium tuberculosis prevalence,” Rheumatology, vol. 48, no. 2, p. 195, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. H. Ferebee and C. E. Palmer, “Prevention of experimental tuberculosis with isoniazid,” The American Review of Tuberculosis and Pulmonary Diseases, vol. 73, pp. 1–18, 1956.
  11. P. R. Donald, F. A. Sirgel, F. J. Botha et al., “The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 3, pp. 895–900, 1997. View at Scopus
  12. D. B. Sneag, H. S. Schaaf, M. F. Cotton, and H. J. Zar, “Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases,” Pediatric Infectious Disease Journal, vol. 26, no. 12, pp. 1142–1146, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. Diel, P. Wrighton-Smith, and J. P. Zellweger, “Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis,” European Respiratory Journal, vol. 30, no. 2, pp. 321–332, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. G. H. Mazurek, J. Jereb, P. LoBue, M. F. Iademarco, et al., “Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States,” MMWR, vol. 54, no. RR15, pp. 49–55, 2005.
  15. American Thoracic Society and US Centers for Disease Control, “Targeted tuberculin testing and treatment of latent tuberculosis infection,” American Journal of Respiratory and Critical Care Medicine, vol. 161, pp. S221–S247, 2000.
  16. National Collaborating Centre for Chronic Conditions, Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control, Royal College of Physicians, London, UK, 2006.
  17. A. Harrison, Ed., “Guidelines for tuberculosis control in New Zealand,” Ministry of Health, 2010, http://www.moh.govt.nz/moh.nsf/indexmh/tuberculosis-control-nz-guidelines-2010.
  18. M. Pai, L. W. Riley, and J. M. Colford, “Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review,” Lancet Infectious Diseases, vol. 4, no. 12, pp. 761–766, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. A. Nienhaus, A. Schablon, and R. Diel, “Interferon-gamma release assay for the diagnosis of latent TB infection—analysis of discordant results, when compared to the tuberculin skin test,” PLoS One, vol. 3, no. 7, Article ID e2665, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. R. N. van Zyl-Smit, A. Zwerling, K. Dheda, and M. Pai, “Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review,” PloS One, vol. 4, no. 12, Article ID e8517, 2009. View at Scopus